Apollon, a developer of noninvasive continuous glucose monitoring (CGM), has been selected for the Ministry of SMEs and Startups' "Global Collaborative R&D Project." Through this project, Apollon plans to collaborate with MIT to develop a next-generation noninvasive CGM and verify its clinical efficacy.
"Global Collaborative R&D" is a new program that supports domestic small and medium-sized venture companies to secure global technological competitiveness and accelerate their entry into overseas markets by conducting joint research and development with leading overseas research institutes. This project will receive a total of KRW 1.5 billion in support over three years, and a total of 49 projects have been selected for 2025.
In this study, Apollon will pursue ▲development of a glucose-specific compact optical system based on Raman spectroscopy ▲development of a small-signal amplifier to improve signal-to-noise ratio (SNR) ▲development of operating hardware for system integration ▲device validation.
The MIT Laser Biomedical Research Center (LBRC) is participating as a global partner. The center is a world-renowned research team that has been conducting Raman spectroscopy-based blood glucose measurement research for nearly 30 years. Dr. Jeon-Woong Kang and Professor Peter Soh are co-principal investigators (PIs). Dr. Kang has been researching noninvasive in vivo blood glucose measurement for over 15 years at Harvard Medical School and MIT, and in 2020, he published a paper in Science Advances confirming the world's first in vivo glucose Raman signal.
“A compact, non-invasive blood glucose meter is not a technology of the distant future, but an innovation that is right before our eyes,” said Apollon CTO Dr. Joo Mi-yeon. “The combination of MIT’s long-standing research achievements and Apollon’s compact optical sensor technology will be able to dramatically improve the lives of diabetics around the world.”
- See more related articles
You must be logged in to post a comment.